Successful use of extended criteria donor grafts with low to moderate steatosis in patients with model for end-stage liver disease scores below 27
- PMID: 19249515
- DOI: 10.1016/j.transproceed.2008.10.050
Successful use of extended criteria donor grafts with low to moderate steatosis in patients with model for end-stage liver disease scores below 27
Abstract
Liver transplantation may be performed using extended criteria donor grafts (ECDg). The characteristics of ECDg include age >60 years, long intensive care unit (ICU) stay, history of malignancy or steatosis. Grafts are often discarded due to steatosis, which can be macrovesicular (MaS) or microvesicular (MiS). MaS is the variety most frequently involved with unfavorable outcomes due to primary nonfunction (PNF) or primary dysfunction (PDF). As of January 2000, all livers referred to our institution were considered potentially transplantable. Steatosis was defined as the presence of fat droplets in more than 5% of hepatocytes. We observed 35 steatotic grafts. Grafts were stratified according to MaS and MiS as follows: low steatosis (5%-15%), mild steatosis (16%-30%), moderate steatosis (31%-60%), or severe steatosis (>60%). Fifteen grafts with moderate (n = 2) or severe (n = 13) MaS were discarded. Twenty grafts were harvested: 18 of them were transplanted at our institution, the remaining 2, discarded by our donor team, were transplanted by other Italian centers. Low MaS was detected in 10 grafts (50%), mild MaS in 4 (20%), and moderate MaS in 2 (10%). Low MiS was detected in 8 grafts (40%), mild MiS in 5 (25%), and moderate MiS in 1 (5%). Steatotic grafts were transplanted only into recipients with model for end-stage liver disease (MELD) scores <27. The 6-month graft survival was 80%; the PNF rate was 10%; and the PDF rate was 15%. The careful use of ECDg with low to moderate steatosis is possible if particular care is taken to avoid additional risk factors related to the recipient.
Similar articles
-
Use of severely steatotic grafts in liver transplantation: a matched case-control study.Ann Surg. 2007 Dec;246(6):940-6; discussion 946-8. doi: 10.1097/SLA.0b013e31815c2a3f. Ann Surg. 2007. PMID: 18043095
-
Assignment of steatotic livers by the Mayo model for end-stage liver disease.Transpl Int. 2005 May;18(5):577-83. doi: 10.1111/j.1432-2277.2005.00091.x. Transpl Int. 2005. PMID: 15819807
-
Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index.J Gastroenterol Hepatol. 2012 Mar;27(3):540-6. doi: 10.1111/j.1440-1746.2011.06844.x. J Gastroenterol Hepatol. 2012. PMID: 21777274
-
Donor liver steatosis and graft selection for liver transplantation: a short review.Eur Rev Med Pharmacol Sci. 2005 Sep-Oct;9(5):295-7. Eur Rev Med Pharmacol Sci. 2005. PMID: 16231593 Review.
-
An approach to the rational use of steatotic donor livers in liver transplantation.Hepatogastroenterology. 1999 Mar-Apr;46(26):1164-73. Hepatogastroenterology. 1999. PMID: 10370686 Review.
Cited by
-
Results of a newborn liver transplant program in the era of piggyback technique and extended donor criteria in Italy.Updates Surg. 2011 Sep;63(3):191-200. doi: 10.1007/s13304-011-0096-1. Epub 2011 Jul 19. Updates Surg. 2011. PMID: 21769698
-
Impact of liver graft steatosis on long-term post-transplant hepatic steatosis and fibrosis via magnetic resonance quantification.Front Med (Lausanne). 2025 Jan 17;11:1502055. doi: 10.3389/fmed.2024.1502055. eCollection 2024. Front Med (Lausanne). 2025. PMID: 39895824 Free PMC article.
-
Short-term and long-term outcomes of liver transplantation using moderately and severely steatotic donor livers: A systematic review.Medicine (Baltimore). 2018 Aug;97(35):e12026. doi: 10.1097/MD.0000000000012026. Medicine (Baltimore). 2018. PMID: 30170411 Free PMC article.
-
The promise of organ and tissue preservation to transform medicine.Nat Biotechnol. 2017 Jun 7;35(6):530-542. doi: 10.1038/nbt.3889. Nat Biotechnol. 2017. PMID: 28591112 Free PMC article. Review.
-
Human-scale whole-organ bioengineering for liver transplantation: a regenerative medicine approach.Cell Transplant. 2013;22(2):231-42. doi: 10.3727/096368912X654939. Epub 2012 Aug 27. Cell Transplant. 2013. PMID: 22943797 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials